JAK2 and acute lymphoblastic leukemia: More than 50% of pediatric patients with Ph-like ALL harbor CRLF2 (cytokine receptor-like factor 2) rearrangements, in which the majority have coexistent Janus kinase gene mutations, such as JAK1 and JAK2, leading to the activation of the JAK/STAT signaling pathway.